Cresco Labs closes PharmaCann acquisition for US$50 million
Cresco Labs announced the closing of its acquisition of 100% of PharmaCann Penn, LLC for aggregate consideration of US$50 million.
Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”) today announced the closing of its acquisition of 100% of the outstanding equity interests in PharmaCann Penn, LLC (“PharmaCann”) for an aggregate consideration of US$50 million (the “Transaction”).
The Transactio…